Wordt geladen...
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Rationale: CD38 is a target for the therapy of multiple myeloma (MM) with monoclonal antibodies such as daratumumab and isatuximab. Since MM patients exhibit a high rate of relapse, the development of new biologics targeting alternative CD38 epitopes is desirable. The discovery of single-domain anti...
Bewaard in:
| Gepubliceerd in: | Theranostics |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Ivyspring International Publisher
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7052896/ https://ncbi.nlm.nih.gov/pubmed/32194826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.38533 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|